BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Tullier, Karla L. eRA COMMONS USER NAME (credential, e.g., agency login)	Clinical Res	POSITION TITLE Clinical Research Nurse Mary Bird Perkins OLOL Cancer Center	
EDUCATION/TRAINING (Begin with baccalaureate or other initial presidency training if applicable.)	rofessional education,	such as nursing, in	clude postdoctoral training and
INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
Southeastern Louisiana University Hammond, LA	BSN	05/01	Nursing

A. Personal Statement

The mission of our cancer center is, "To improve survivorship and lessen the burden of cancer through expert treatment, compassionate care, early detection, research and education." As a registered nurse with years of experience in patient care, my role in the Clinical Research Department directly contributes to our organizational mission. My contributions are made not only directly through our active research projects but also through patient and family education, volunteer work and collaboration with others in my own department as well as the medical and radiation oncologists, social workers/navigators, infusion nurses and nurse practitioners that comprise our comprehensive team.

My integral job duties include; screening and enrolling patients, educating patients and their families on their diagnosis, treatment and management of adverse events. I assist the patients with scheduling appointments, procedures, or other required activities and overcoming any barriers that may surface.

I am involved with promoting clinical research trials and awareness through the annual minority fair, Fest for Life, and at monthly free breast screenings at a local hospital. I am actively involved in screening and recruitment for the majority of the trials included on the NCCCP log as well as many others. Working collaboratively with the LSUHSC MB-CCOP, performing as the primary research nurse for our participation in the Moffitt Cancer Center's Total Cancer Care biospecimen program and consenting greater than 1900 patients, and our current work the Cancer Genome Atlas Program positions me to continue to work with the NCI on the newly formed N-CORP, if we are chosen as a site in 2014.

Personally, I have lost many family members to cancer so I consider it an honor to work with such a progressive organization and innovative team. The compassion and integrity that Mary Bird Perkins Cancer Center shows is echoed in the comments of patients and families. Many times I have been stopped outside of work by people who say, "I see your uniform and just want to say thank you for what you do."

B. Positions, Memberships and Certifications

Positions and Employment

2001 – 2005	Staff Nurse (Telemetry, CICU, SICU), Baton Rouge General Medical Center
2005 – 2008	Circulating/Charge Nurse, Vascular Specialty Clinic
2008 – 2010	Director or Surgical Services, Vascular Specialty Clinic and Cardiovascular & Thoracic
	Specialists
2010 –	Clinical Research Nurse, Mary Bird Perkins – OLOL Cancer Center

Professional Memberships

2011 - Member, Oncology Nursing Society

2011 - Member, Baton Rouge Oncology Nursing Society

License and Certifications

2001 - Registered Nurse, Louisiana State Board of Nursing

C. Selected Peer-reviewed Publications

None.

D. Research Support

MBPCC-PS-1204 (Celldex) Olson (PI) 5/16/2012 - Vaccine therapy among newly diagnosed glioblastoma patients.

The primary objective of the study is to confirm that the addition of rindopepimut/GM-CSF to adjuvant temozolomide improves overall survival in patients with newly diagnosed EGFRvIII positive glioblastoma who have undergone gross-total resection.

KLT PANC-001 Bienvenu (PI) 6/3/2013 -

Advanced pancreatic cancer.

The goal of this study is to compare the effect of gemcitabine + Kanglaite Injection (KLTi) to gemcitabine alone in patients with locally advanced or metastatic pancreatic cancer, not amenable to curative surgical resection.

PH3-01 (Present) Spell (PI) 12/20/2011 -

Vaccine therapy in early stage HER2 low breast cancer.

The primary objective is to compare the disease-free survival (DFS) in subjects with operable early-stage, node-positive breast cancer who receive standard of care multimodality therapy plus NeuVax with rhGM-CSF as the treatment group or standard of care multimodality therapy plus the placebo with the vaccine adjuvant, rhGM-CSF (sargramostim) as the control group.

NSABP B-43 Veith (PI) 12/19/2009 -

HER2-Positive Ductal Carcinoma In Situ

The primary aim of this trial is to determine whether trastuzumab given concurrently with radiation therapy is more beneficial in preventing subsequent ipsilateral breast cancer recurrence, ipsilateral skin cancer recurrence, or ipsilateral DCIS, when compared with radiation therapy alone in women with HER2-positive ductal carcinoma in situ (DCIS) resected by lumpectomy.

RTOG 1008 Veith (PI) 10/18/2011 -

Malignant salivary gland tumors.

Acquire preliminary efficacy data comparing postoperative radiotherapy alone to concurrent chemotherapy and radiation using weekly cisplatin.

CALGB 80702 Veith (PI) 6/22/2010 -

Resected Stage III Colon Cancer.

To compare disease-free survival of patients with stage III colon cancer randomized to standard chemotherapy only (FOLFOX) or standard chemotherapy (FOLFOX) with 3 years of celecoxib 400 mg daily.

ECOG E3F05 Veith (PI) 2/9/2011 -

Symptomatic or progressive low grade gliomas.

To determine whether the addition of temozolomide to fractionated radiotherapy improves the progression-free survival (PFS) and median overall survival (OS) of patients requiring treatment for low-grade gliomas.

TALC McWhorter (PI) 7/28/2011 -

Laryngeal cancer observational study.

The immediate goals of this study are to compare the impact of primary chemoradiation versus surgery on patients with new tumors of the hypopharynx and cartilage-invading larynx) that would require total laryngectomy for cure.

MCC14690 (Total Cancer Care) Vincent (PI) 10/01/2008 -

Created a clinical data and tissue repository.

The overall objective of this study is to develop an improved standard of cancer care by facilitating new clinical trials, new technology, new informatics solutions and "personalized medicine."

TCGA (Total Cancer Genome Atlas Project) Vincent (PI) 09/2013 -

Biospecimen procurement program.

The TCGA project is designed to try to identify all of the genetic changes that can cause cancer in people by studying the genetic and biochemical material from various types of cancer tissue collected.

Connect CLL Bienvenu (PI) 4/27/2010 -

Chronic Lymphocytic Leukemia Disease Registry

Describe practice patterns of first-line therapy regimens and subsequent therapeutic strategies in patient initiated on therapy for CLL, as well as initiated on second line and subsequent therapies, in the community and academic setting.

Completed Research Support

NCIC MA.32 Veith (PI) 11/10/2010 - 1/23/2013

Early stage breast cancer.

To compare invasive disease free survival (IDFS) between subjects treated with metformin (850 mg po bid for 5 years) versus placebo in addition to standard adjuvant therapy.

CCCWFU 98110 Veith (PI) 2/11/2011 - 11/18/2013

Erectile dysfunction.

To determine the "best dose" of ArginMax to be used in a subsequent Phase III trial.

NLG-0405 Bienvenu (PI) 5/11/2012 - 9/17/2013

Surgically resected pancreatic cancer.

To assess overall survival after treatment with a regimen of adjuvant therapy (gemcitabine alone or with 5-FU chemoradiation) with or without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in subjects who have undergone surgical resection.

DFCI (Young & Strong) Schmeeckle (PI) 10/25/2012 - 9/12/2013

Young women with breast cancer.

The overall objective of this study is to determine the effect of an education and support intervention for young women with breast cancer and their oncology providers (YWI) on attention to fertility issues compared to a physical activity comparison intervention (PAI) in a randomized controlled trial.

SWOG S0702 Veith (PI) 6/25/2013 - 12/13/2013

Incidence of osteonecrosis of the jaw in patients receiving Zometa.

The primary objective of this study is to prospectively assess the cumulative incidence of osteonecrosis of the jaw (ONJ) at 3 years in cancer patients with bone metastasis receiving zoledronic acid treatment.

MBPCC-PS 11-04 (Sciclone) Bienvenu (PI) 7/25/2011 - 7/29/2013

Oral Mucocitis

